信立泰(002294.SZ)：SAL0140获临床试验批准

Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating primary aldosteronism [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company [1] - The drug is intended to target indications including uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1]